# LL-37: Thousands of Papers, No Human Trials By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-21 | Updated: 2026-10-27 Canonical page: https://glpwatchdog.org/research/ll-37-a-peptide-with-no-human-trials > LL-37 is the body's own cathelicidin and the subject of thousands of papers. Read what they are and it is structural biology, cell culture and mice, including a wound-healing study in diabetic mice. We found no human clinical trial. ## Key points - No human clinical trial of LL-37 supplementation was found for wound healing, immunity or recovery. - The wound-healing result is a full-thickness model in diabetic mice. An autophagy inhibitor reversed it, and TFEB knockdown impaired LL-37's effect in cultured skin cells. - LL-37 is the only cathelicidin-family antimicrobial peptide humans make, a molecule the body already regulates. - The same review covering its antimicrobial promise also covers its influence on amyloid-related disease. Search LL-37 and you will find thousands of papers, which is what makes it easy to sell. Read what they are and the picture changes: structural biology, cell culture, and animals. The most cited wound-healing result is a full-thickness wound model **in diabetic mice**, and its mechanism was confirmed by knocking down a transcription factor in cultured keratinocytes.[1] That is respectable science, but it gives no reason to inject yourself with anything. ## What LL-37 actually is LL-37 is the only cathelicidin-family antimicrobial peptide humans make. It is 37 residues long and part of the innate immune system’s first line of defense against bacteria, viruses, fungi and parasites. Interest in it is largely driven by antibiotic resistance: a broad-spectrum natural antimicrobial is an attractive starting point for new drugs.[2] That origin cuts both ways, and it is the part the marketing does not dwell on. A molecule your body already produces and regulates carefully is not obviously one to add from outside at an unregulated dose. The same review that surveys its antimicrobial promise also covers its influence on amyloid-related disease, because a peptide that aggregates and interacts with other aggregating proteins has consequences beyond killing bacteria.[2] ## The wound-healing study, described accurately Researchers established a full-thickness wound closure model in diabetic mice and tested LL-37 against LL-37 plus an autophagy inhibitor. LL-37 improved wound healing; adding the inhibitor reversed it. In cell culture, LL-37 promoted keratinocyte migration under high glucose, and knocking down the transcription factor TFEB impaired that effect.[1] > This is a well-built mechanistic study. It shows an effect, identifies the pathway, and then removes the pathway to confirm it. **It is also mice and cells, and the gap between a healed mouse wound and a healed human one is where most drug candidates die.** ## Why the paper count misleads The most common way peptide marketing establishes credibility is volume: hundreds of citations, decades of research, a named human molecule. All of that is true, and none of it amounts to a controlled trial in people showing a benefit at a dose somebody sold you. > Thousands of papers on LL-37, and we found no human clinical trial of it as a supplement. - We found no human clinical trial of LL-37 supplementation for wound healing, weight, immunity or recovery. - It is not an approved medicine. Anything sold under the name is a research chemical, with no guarantee of identity, purity or dose. - Its biology is double-edged: an innate immune peptide with documented involvement in amyloid-related disease processes. - Anyone with a diabetic wound has a condition that needs clinical wound care. A mouse study is not a treatment plan. [KPV](https://glpwatchdog.org/research/kpv-peptide-what-the-evidence-shows), sold for gut and skin inflammation, is in the same position as LL-37. For the class of drug that does have randomized evidence in diabetic foot disease, see [GLP-1s, diabetic foot ulcers and blood flow](https://glpwatchdog.org/research/glp1-diabetic-foot-ulcers-and-perfusion). For the regulatory position on research-use peptides generally, see [what FDA actually said about BPC-157](https://glpwatchdog.org/research/bpc-157-what-fda-actually-said), and [/peptides](https://glpwatchdog.org/peptides) lists the peptides we profile in full. ## Frequently asked questions ### Is there human evidence for LL-37? We found no human clinical trial of LL-37 supplementation. The literature is structural biology, cell culture and animal models, including a wound-healing study in diabetic mice with mechanistic confirmation in cultured cells. ### What is LL-37? It is the only cathelicidin-family antimicrobial peptide humans produce, 37 amino acids long, and part of the innate immune system's first-line defense against bacteria, viruses, fungi and parasites. ### Does LL-37 heal wounds? In diabetic mice it improved wound closure, and an autophagy inhibitor reversed that effect. In cultured skin cells, knocking down the transcription factor TFEB impaired its effect on cell migration. That is good evidence for the mechanism in those models. No human trial has tested it. ### Is it safe to take? That has not been established in people. LL-37 is a molecule the body produces and regulates itself, its biology includes involvement in amyloid-related disease processes, and any product sold under the name is an unapproved research chemical without identity or purity guarantees. ## References 1. Xi L, Du J, Xue W, et al. Cathelicidin LL-37 promotes wound healing in diabetic mice by regulating TFEB-dependent autophagy. Peptides. 2024. PMID: 38423213. https://pubmed.ncbi.nlm.nih.gov/38423213/ 2. Bhattacharjya S, Zhang Z, Ramamoorthy A. LL-37: Structures, Antimicrobial Activity, and Influence on Amyloid-Related Diseases. Biomolecules. 2024. PMID: 38540740. https://pubmed.ncbi.nlm.nih.gov/38540740/ --- Cite as: GLP Watchdog, Nora Bissett, "LL-37: Thousands of Papers, No Human Trials", published 2026-08-21, updated 2026-10-27. https://glpwatchdog.org/research/ll-37-a-peptide-with-no-human-trials Canonical HTML page: https://glpwatchdog.org/research/ll-37-a-peptide-with-no-human-trials Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.